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ABSTRACT
The goal of this study was to characterize longitudinal changes in bone microarchitecture and function in women treated with an
establishedantifracturetherapeutic.Inthisdouble-blind,placebo-controlledpilotstudy,53earlypostmenopausalwomenwithlowbone
density (age¼56 4 years; femoral neck T-score¼ 1.5 0.6) were monitored by high-resolution peripheral quantitative computed
tomography (HR-pQCT) for 24 months following randomization to alendronate (ALN) or placebo (PBO) treatment groups. Subjects
underwent annual HR-pQCT imaging of the distal radius and tibia, dual-energy X-ray absorptiometry (DXA), and determination of
biochemicalmarkersofboneturnover(BSAPanduNTx).Inadditiontobonedensity andmicroarchitecture assessment, regionalanalysis,
cortical porosity quantification, and micro-finite-element analysis were performed. After 24 months of treatment, at the distal tibia but
not the radius, HR-pQCT measures showed significant improvements over baseline in the ALN group, particularly densitometric
measures in the cortical and trabecular compartments and endocortical geometry (cortical thickness and area, medullary area) (p<.05).
Cortical volumetric bone mineral density (vBMD) in the tibia alone showed a significant difference between treatment groups after
24 months (p<.05); however, regionally, significant differences in Tb.vBMD, Tb.N, and Ct.Th were found for the lateral quadrant of the
radius (p<.05). Spearman correlation analysis revealed that the biomechanical response to ALN in the radius and tibia was specifically
associated with changes in trabecular microarchitecture (jrj¼0.51 to 0.80, p<.05), whereas PBO progression of bone loss was
associated with a broad range of changes in density, geometry, and microarchitecture (jrj¼0.56 to 0.89, p<.05). Baseline cortical
geometry and porosity measures best predicted ALN-induced change in biomechanics at both sites (r > 0.48, p<.05). These findings
suggest a more pronounced response to ALN in the tibia than in the radius, driven by trabecular and endocortical changes.  2010
American Society for Bone and Mineral Research.
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Introduction
O
steoporosis is a condition characterized by loss of bone
mass and deterioration of microarchitecture, and it
manifests clinically as an increased risk of fracture.
(1) Currently,
determination of fracture risk is based primarily on bone
mineral density (BMD) values obtained through areal or
volumetric X-ray-based imaging techniques. While BMD has
been shown to have utility in predicting bone strength, it
does not entirely determine fracture risk
(2,3) or adequately
assess the full impact of therapeutic interventions.
(4,5) For
these reasons, much interest currently is directed at the
investigation of other factors associated with bone mechanical
competence and therapeutic response, including whole-bone
geometry, cortical and trabecular microarchitecture, and tissue
composition.
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2558Analysis of bone structure is critical to understanding bone
mechanics, assessing fracture risk, and evaluating responses to
disease, age, and therapy. Improved predictions of biomecha-
nical properties have been found as a result of including
measures of trabecular bone structure in statistical regres-
sions.
(6,7) Trabecular bone structure is also critical in the
evaluation of therapeutic interventions, enabling researchers
to explain a greater proportion of the effect of drugs on fracture
risk than BMD alone.
(8,9) Therefore, structural analysis is a
particularly important aspect of bone quality assessment.
High-resolution peripheral quantitative computed tomogra-
phy (HR-pQCT) has been introduced recently as a noninvasive
methodforinvivo3Dcharacterizationofbonemicroarchitecture
in humans. Similar to traditional quantitative computed
tomography (QCT), HR-pQCT provides the ability to quantita-
tively assess volumetric bone mineral density (vBMD) in a
compartmental fashion. Additionally, it permits quantification of
the geometric, microarchitectural, and mechanical features of
humancortical and trabecular bonein the appendicular skeleton
(distalradiusand tibia).This imagingtechniquehasbeen applied
in a number of cross-sectional studies to characterize aging
effects,
(1,10–14) fracture discrimination,
(15–18) and various pathol-
ogies.
(19–21) The potential of HR-pQCT to provide longitudinal in
vivo assessment of bone quality with respect to therapeutic
efficacy is of particular interest, although, to date, few
longitudinal results have been reported.
(19,22)
In this study, HR-pQCT has been used to conduct a 2-year
longitudinal evaluation of the response to an established
antiresorptive therapeutic agent (alendronate) in the distal
radius and tibia of early postmenopausal women with low bone
density. Previously, comparisons between baseline HR-pQCT and
high-resolution magnetic resonance imaging (MRI) microarch-
itectural measures were reported by Kazakia and colleagues for
this cohort.
(23) Our aims for the longitudinal component of this
study were (1) to characterize the densitometric, geometric,
microarchitectural, and biomechanical cortical and trabecular
bone changes in subjects treated for 24 months with
alendronate compared with placebo, (2) to investigate the
relationship between bone density and structure and functional
changes, as measured by biochemical markers of bone turnover
and estimates of bone strength determined by micro-finite-
element analysis (mFEA) following treatment with alendronate,
and (3) to investigate the relationship between baseline bone
densityandstructure phenotypes andthe functionalresponseto
alendronate therapy.
Materials and Methods
Subjects
A longitudinal pilot imaging study comparing the effects of
alendronate with those of placebo (calcium and vitamin D) on
bone microarchitecture was conducted in a total of 53
community-dwelling, ambulatory, postmenopausal women
defined as osteopenic by World Health Organization (WHO)
criteria.
(24) A detailed baseline characterization of this study
group has been reported elsewhere.
(23) The women were
between the ages of 45 and 65 years, with a mean age of 55.6
years (Table 1). The women were postmenopausal for at least 1
but not more than 6 years, with a mean duration of 31 months
postmenopause. The subjects had low BMD levels (T-score range
 1.1 to  2.5) by dual-energy X-ray absorptiometry (DXA) at
either the lumbar spine or the total proximal femur, trochanter,
or neck regions of interest. A total of 53 women were
randomized 1:1—26 in the treatment group [70 mg of
alendronate once weekly and daily 2800 IU of vitamin D3 and
OSCalþD(1000mgofcalciumþ400IUofvitaminD3)]and27in
the placebo group [daily 2800 IU of vitamin D3 and OSCal þ D
(1000 mg of calcium þ 400 IU of vitamin D3)]. The study size was
based on power calculations of previous longitudinal mMRI data
indicating a required sample size of 23 per group in order to
detect a treatment difference of 5% (power¼0.95, a¼0.05) in
trabecular number at the distal radius.
(25) Exclusion criteria
included a history of fracture after age 50, history of or evidence
for metabolic bone disease other than postmenopausal bone
loss, treatment within the previous year with any compound
known to influence bone turnover, and estrogen use within the
past 6 months. Other exclusion criteria related to indications for
specific imaging techniques included in the full study protocol
(DXA, HR-pQCT, and MRI) were subject weight greater than 250
lb (113.4 kg), the presence of a pacemaker, and claustrophobia.
The UCSF Committee of Human Research approved the study
protocol, and all patients gave written informed consent prior to
participation.
DXA measurements
Bone densitometry data were acquired using DXA at the lumbar
spine, proximal femur (neck, trochanter, and total proximal
femur), and distal radius (ultradistal and distal one-third radius).
At baseline, 42 subjects were scanned with the QDR 4500
(Hologic, Inc., Bedford, MA, USA) and 11 subjects using the Lunar
Table 1. Study Participant Characteristics
a
Baseline 24 months
PBO (n¼27) ALN (n¼26) PBO (n¼13) ALN (n¼20)
Age (years) 55.4 3.3 55.8 3.9 56.4 2.4 56.1 4.1
Total-hip T-score  0.8 0.6  0.8 0.6  0.8 0.5  0.7 0.7
Lumbar spine T-score  1.0 0.7  1.2 0.7  1.1 0.7  1.1 0.7
Months since menopause 31.5 17.8 30.5 17.4 33.5 18.6 32.0 16.6
aNo statistically significant differences between PBO and ALN at baseline or 24 months.
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ments were obtained on the same scanner for each subject.
T-scores were calculated at all sites based on the standard Third
National Health and Nutrition Examination Survey (NHANES III)
database.
Biochemical markers of bone turnover
Laboratory parameters used to evaluate changes in bone
turnover included urinary N-telopeptide of type I human
collagen (uNTx; Osteomark NTx EIA, Inverness Medical Profes-
sional Diagnostics, Princeton, NJ, USA) corrected for creatinine
(Cr; Roche Diagnostics, Indianapolis, IN, USA) to assess the rate of
bone resorption and serum bone-specific alkaline phosphatase
(BSAP; MicroVue BAP EIA, Quidel Corporation, San Diego, CA,
USA) to assess the rate of bone formation. Stored samples were
analyzed by a central laboratory (Pacific Biometrics, Seattle, WA,
USA) in batches by patient at the end of the study. All
biochemicalmarkersofboneturnoverwereobtainedatbaseline,
12 months,and24 months whilesubjects werefasting. uNTxwas
measured from second-morning-void urine samples.
HR-pQCT imaging
All subjects were imaged in a clinical HR-pQCT system
(XtremeCT, Scanco Medical AG, Bru ¨ttisellen, Switzerland) using
the manufacturer’s standard in vivo protocol described in
previous patient studies.
(15–17) The subject’s forearm/ankle was
immobilized in a carbon fiber cast that was fixed within the
gantry of the scanner. Asingle dorsal-palmar projection image of
the distal radius/tibia was acquired to define the tomographic
scan region. This region spanned 9.02 mm in length (110 slices)
and was fixed starting at 9.5 and 22.5 mm (for the radius and
tibia, respectively) proximal from the middle joint line and
extending proximally. For tomography, 750 projections were
acquired over 180 degrees with a 100-ms integration time at
each angular position. The 12.6-cm field of view (FOV) was
reconstructed across a 1536   1536 matrix using a modified
Feldkamp algorithm, yielding 82-mm voxels.
(26) Total scan time
was 2.8 minutes, with an effective dose of approximately 4.2 mSv
for each site. Representative cross-sectional and 3D images are
shown in Fig. 1.
HR-pQCT analysis
Image registration
All longitudinal analyses were constrained to a common volume
of interest (VOI) between baseline and 12- and 24-month
measurements. This common region was identified using
software provided by the manufacturer. The method computes
periosteal cross-sectional area on a slice-by-slice basis for each
time point and then determines an optimal offset between scans
using a cross-correlation approach. As a result, the VOI generally
was less than the full 110 slices acquired (average 103 slices). All
subsequent analyses of HR-pQCT data were applied to the
common VOI determined in this fashion.
Standard analysis
HR-pQCT images were evaluated using the standard clinical
evaluation protocol, adapted from methods developed for a
previous pQCT device.
(27,28) First, the periosteal perimeter was
identified using a semiautomated edge-finding algorithm that
produces a closed contour around the periosteal surface. The
total volumetric bone mineral density (vBMD) was calculated
from the volume contained within this contour. The cortical
compartment VOI was segmented using a 3D Gaussian operator
to smooth out the trabecular structure followed by a fixed
threshold (16% of the positive integer space) to separate
mineralized cortex from background. Cortical vBMD (Ct.vBMD)
was calculated as the mean density of voxels in the segmented
cortical VOI. Cortical thickness (Ct.Th) was calculated using an
annular modelapproximation: cortical area (Ct.Ar) divided by the
periosteal perimeter. The trabecular compartment was identified
by subtraction of a mask of the cortical compartment from a
mask of the full region encompassed by the periosteal contour.
The trabecular bone volume to total volume ratio (BV/TV) was
derived from the BMD of the trabecular VOI (Tb.vBMD) and
Fig. 1. Representative 2D and 3D images of the radius (A, B) and tibia (E, F) of a study participant. Definitions for region-based analyses and the
segmentation of intracortical porosity are also shown for the radius (C, D) and tibia (G, H).
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density of 1200 mg hydroxyapatite (HA)/cm
3, whereas the
marrow background is equivalent to 0 mg HA/cm
3. Extraction of
the trabecular structure was performed as follows: A Laplace-
Hamming filter—which effectively smoothes the image and
enhances edges—was applied to the original grayscale data,
and a fixed global threshold (40% of the positive integer space)
was applied to discretize the bone and background phases.
(29)
From the binary image, Tb.N was calculated directly by
computing the mean of the 3D distance between trabecular
midaxes.
(30,31) The standard deviation of those distances (Tb.1/
N.SD) also was calculated to represent the spatial heterogeneity
of the microarchitecture. Based on the densitometric BV/TV and
direct Tb.N, Tb.Th and Tb.Sp were derived using traditional plate
model assumptions.
(32)
Subregional analysis
Inadditiontothestandardpatient-styleevaluation,whichresults
in a global average value for the entire volume, the following
process for defining subregions was performed automatically
using a method described recently by Sode and colleagues.
(33)
The trabecular compartment was divided into two concentric
regions (inner and outer subregions), where the area of the inner
subregion was 60% of the entire trabecular region. The volume
was divided further into axial quadrants. In the lower limb, a line
connecting the axial centroids of the tibia and fibula and its
orthogonal complement defined approximately mediolateral/
anteroposterior quadrants. In the forearm, the major and minor
axes of the axial cross section of the radius defined mediolateral/
anteroposterior quadrants. A total of 8 subregions resulted, as
shown in Fig. 1C, G. Each subregion was denoted by a two-letter
acronym based on location: I or O for inner or outer subregions,
respectively, and M, P, L, or A for medial, posterior, lateral, or
anterior, respectively (Fig. 1C, G). Mean cortical and trabecular
densitometric and microarchitectural indices were computed for
each individual subregion.
Extended cortical bone analysis
As reported previously, the default cortical bone analysis
performs poorly for subjects with very thin or highly porous
cortices.
(23,34) Accordingly, a fully automated cortical compart-
ment segmentation technique adapted from the method
described previously by Buie and colleagues was applied.
(34,35)
To exclusively segment the intracortical porosity volume, a novel
algorithm based on 2D component labeling and a 3D region-
growing process was applied.
(36) True intracortical porosity was
estimated initially to be all void voxels unconnected to the
background in each 2D axial slice. Next, a region-growing
process additionally included void voxels connected along the z
axis (SI direction) to the initial pore voxel (Fig. 1D, H). Based on
this segmentation of the intracortical pore volume (Ct.PoV),
intracortical porosity (Ct.Po) was defined as a normalized
volumetric index according to Eq. (1):
Ct:Po ¼
Ct:PoV
Ct:PoV þ Ct:BV
(1)
where Ct.BV is the mineralized cortical bone volume. Based on
this segmentation, a direct 3D calculation
(30) of cortical thickness
(Ct.Th
 ) was performed on the composite segmentations of the
mineralized cortex and porosity, thereby disregarding intracor-
tical pore surfaces in the local distance calculations. This index
represents a direct 3D measure of endosteal-periosteal distance.
Previous reproducibility measurements in 27 postmenopausal
women indicated the least significant change for Ct.Po to be
0.57% (RMSCV%¼11.7%) for the distal radius and 0.92%
(RMSCV%¼3.9%) for the distal tibia.
mFE analysis
Linear micro-finite-element analysis (mFEA) was applied to
calculate apparent biomechanical properties under uniaxial
compression. Homogeneous mechanical properties were
assumed for all bone elements. The binary image data set was
converted to a mesh of isotropic brick elements using a voxel
conversion technique,
(37) and each element was assigned an
elastic modulus of 10 GPa
(38) and a Poisson’s ratio of 0.3.
(39)
Cortical and trabecular bone elements were labeled as different
materials with identical material properties to facilitate calculation
of compartmental load distribution. A uniaxial compression test
in the axial direction (superoinferior) was performed with an
applied strain of 1%. An iterative solver (Scanco FE Software,
Version 1.12, Scanco Medical) was used to compute reaction
forces at the proximal and distal ends of the scan region for
the prescribed displacements. The model computations were
performedattheUCSF/QB3SharedComputingFacility—amixed-
architecture Linux HPC grid consisting of 1900 processor nodes.
No models were excluded owing to convergence limitations.
For each model, stiffness K, apparent modulus E, and the load
fraction for the cortical compartment (Ct.LF) at the distal
boundary were calculated. Furthermore, failure load F was
estimated using methods previously described by Pistoia and
colleagues.
(40) Differential biomechanical indices related to
cortical porosity also were calculated by running a second
model for each specimen with intracortical pore spaces digitally
occluded.
(36) Specifically, the deficit in stiffness DKPO, apparent
modulus DEPO, and failure load DFPO owing to the resolvable
intracortical porosity were calculated as the difference in the
respective parameter between the occluded and original models
and normalized by the original. These indices were reported as a
percent. The fractional load (DCt.LFPO) shifted from the cortex to
the trabecular bone was calculated simply as the difference
between occluded and original Ct.LF.
Statistical analysis
The statistical analysis was performed on a per-protocol basis.
Thechangefrom baselineat12 and24months forallparameters
was expressed as the percent difference from baseline in
alendronate-treated (ALN) and placebo-treated (PBO) groups.
The statistical significance of the change with respect to baseline
as well as between treatment groups was assessed using a two-
way analysis of variance with repeated measures on time
(RMANOVA).Nonparametric Spearman correlations were used to
characterize the response to ALN or PBO treatment. For the
purposes of this analysis, response was considered to be
absolute change in the biomarkers uNTx/Cr and BSAP as well as
the percent change in mFEA-derived biomechanical indices
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relationships were investigated: (1) the association between
changes in BMD, geometry, and microarchitecture and response
to ALN and PBO treatment at 24 months and (2) whether
baseline bone turnover, BMD, microarchitecture, or biomecha-
nics predicted the subsequent response to ALN treatment after
24 months. A significance level of p<.05 was considered
statistically significant. All statistical tests were performed using
JMP (Version 7.0, SAS Institute, Inc., Cary NC, USA).
Results
Final subject disposition
The 24-month subject attrition rate was 23% for the ALN group
(n¼20) and 52% for the PBO group (n¼13). One PBO-treated
subject was removed by the principal clinical investigator
(blinded to treatment) owing to a large decrease in BMD after
12 months. The remaining dropouts were due to elective
withdrawals (PBO¼6, ALN¼3), adverse events (PBO¼3,
ALN¼2), nonadherence (PBO¼2, ALN¼1), or unrelated health
issues (PBO¼1, ALN¼1). For the subjects who completed the
full 24-month study, there were no statistically significant
differences in the primary screening inclusion measures (base-
line age, months since menopause, total-hip T-score, and total-
spine T-score) between the ALN and PBO groups (Table 1).
Treatment effects on turnover, density, geometry,
microarchitecture, and strength
Biochemical markers of bone turnover and DXA
There was a significant reduction in both BSAP and uNTx
between baseline and follow-up visits for both the PBO and ALN
Fig. 2. Time-series line plots of the percent change in distal radius HR-pQCT densitometric, geometric, microarchitectural and biomechanical indices for
ALN-treated subjects (black circle) and PBO controls (white box). Cortical thickness is presented as calculated by the standard analysis (solid line) and from
the direct 3D endosteal to periosteal distance after removing intracortical pore surfaces (dashed line). (
ap<.05;
bp<.01;
cp<.001;
dp<.0001 versus
baseline;
ap<.05,
bp<.01,
xp<.001,
dp<.0001 ALN versus PBO).
2562 Journal of Bone and Mineral Research BURGHARDT ET AL.groups (p<.05). A significantly greater reduction in bone
turnover was seen with ALN than with PBO after 12 and
24 months (p<.0001).
Lumbar spine DXA areal BMD (aBMD) values increased in the
treated group (p<.0001), whereas the PBO group showed
maintenance at 12 months and a small decline at 24 months.
Treatment effects in the spine were significant at both 12 and
24 months (p<.0001). Increases in aBMD were greater in the
lumbar spine compared with the total hip, although the ALN
group showed significant changes from baseline (p<.001) and
compared with PBO (p<.05) at both sites. Both total and
ultradistal forearm densities were maintained in the ALN group
and dropped significantly in PBO-treated subjects (p<.05;
except at 12 months for the ultradistal forearm). Significant
treatment effects were observed for the ultradistal forearm
(p<.05) but not for the total forearm.
Longitudinal and treatment effects on HR-pQCT parameters
In the distal radius (Fig. 2), HR-pQCT density measures tended to
decrease after 12 and 24 months in the PBO-treated cohort. This
decrease was statistically significant only for Tb.vBMD after
12 months (p<.05). In contrast, ALN-treated subjects tended to
maintain bone density, with significant treatment differences for
totalvBMDandTb.vBMDat12months(p<.05).LossofTb.vBMD
was particularly pronounced in the outer posterior region for
PBO subjects ( 3%, p<.05; Fig. 3), which, by comparison, was
preserved in ALN-treated subjects (p<.05; Fig. 4). Additionally, a
Fig. 3. Mean percent differences in Tb.vBMD, Tb.N, and Ct.Th at each region of the distal radius and tibia at 24 months compared with baseline for each
group.
ap<.05;
bp<.01;
cp<.001;
dp<.0001; otherwise, not significant.
Fig. 4. A graphic table summarizing the regions wherea significant treatment effect was observed for trabecular and corticalparameters after 24 months
(highlighted in light gray), determined by MANOVA with time as a repeated measure with a¼0.05.
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lateral region of the radius (p<.05).
No significant longitudinal or treatment-wise effects were
seen for the global geometry in the distal radius, although
cortical thickness and area tended to decrease whereas
medullary area tended to increase in PBO subjects. This was
marked by a significant decrease ( 10%, p<.05) in Ct.Th and
Ct.Ar of the lateral cortical region that was maintained with ALN
treatment (p<.05). Similarly, no significant longitudinal or
treatment effects were seen for global trabecular microarchi-
tecture measures in the radius; however, at 24 months,
significant treatment-wise differences were found for Tb.N of
the lateral regions (p<.05), which decreased in PBO subjects
( 2% to 4%, not significant with respect to baseline) and
increased with ALN (þ3% to 4%, not significant with respect to
baseline).
Finite-element estimates of bone strength at the distal radius
decreased significantly for both PBO and ALN cohorts at 12 and
24 months with respect to baseline (p<.05), with the exception
of apparent modulus and failure load at 24 months for ALN.
While the loss of bone strength tended to be less for the ALN-
treated cohort, the treatment effect did not reach statistical
significance.
In the distal tibia (Fig. 5), total vBMD increased significantly
with ALN treatment after 12 and 24 months (p<.05 and
p<.001, respectively). Cortical density decreased significantly at
12 but not 24 months (p<.05), whereas ALN significantly
maintained Ct.vBMD compared with PBO at 12 and 24 months
(p<.05 and p<.01, respectively). While global trabecular vBMD
increased significantly for ALN-treated subjects (p<.05), a
significant treatment effect was found only for the inner lateral
region (p<.05), which increased by þ4% in the ALN group
Fig. 5. Time-series line plots of the percent change in distal tibia HR-pQCT densitometric, geometric, microarchitectural, and biomechanical indices for
ALN-treated subjects (black circle) and PBO controls (white box). Cortical thickness is presented as calculated by the standard analysis (solid line) and from
the direct 3D endosteal to periosteal distance after removing intracortical pore surfaces (dashed line).
ap<.05,
bp<.01,
cp<.001,
dp<.0001 versus
baseline;
ap<.05,
bp 0.01,
xp<.001,
dp<.0001 ALN versus PBO.
2564 Journal of Bone and Mineral Research BURGHARDT ET AL.(p<.05 with respect to baseline) and decreased by  2% in the
control (not significant with respect to baseline).
Tibial geometry was altered significantly at all time points by
ALN. In particular, both the areal estimate and the direct 3D
measure of cortical thickness increased by 3% to 4% at
24 months (p<.0001 for both). Similarly, cortical area increased
and medullary area decreased significantly at 24 months
(p<.0001 for both). While the global geometric changes did
not differ significantly between treatment cohorts, significant
treatment effects on Ct.Th and Ct.Ar between ALN and PBO were
found for the lateral cortical quadrant at 24 months (p<.05).
Cortical and trabecular microarchitecture alterations were not
detected globally nor within any subregion, and no difference
was observed between ALN and PBO groups.
No longitudinal or treatment-wise effects were found for
mFEA estimates of bone strength at the distal tibia. However,
stiffness and failure load tended to increase with ALN and
decrease with PBO. The load fraction supported by the cortex
was significantly increased following 12 and 24 months of ALN
(p<.01).
Bone changes associated with the functional response to
treatment
The Spearman rank correlation coefficient for the 24-month
change in each index with respect to the 24-month change in
biochemical markers of bone turnover and mFEA-derived axial
stiffness K and cortical load fraction (Ct.LF) are presented in
Tables 2 and 3 for the distal radius and tibia, respectively.
In the distal radius (Table 2), the change in biomarker
measures after 24 months generally correlated poorly with the
change in HR-pQCT measures in the PBO and ALN groups.
However, the change in biomechanical measures at 24 months
was found to correlate significantly with a number cortical and
trabecular bone changes in PBO-treated subjects. In contrast, the
biomechanical response to ALN treatment was specifically
associated with changes in trabecular microarchitecture alone
(0.51  j rj 0.80, p<.05); the change in Tb.N was strongly
negativelycorrelated withthe changeinstiffness (Fig. 6),and the
changes in Tb.Th and Tb.Sp were equally positively correlated
with the change in stiffness.
In the distal tibia (Table 3), similar structure-function relation-
ships were observed. For both the PBO and ALN groups, the
changes in biomarker measures were not found to correlate
significantly with changes in HR-pQCT measures or density or
structure measures. In the PBO cohort, the 24-month change in
stiffness significantly correlated with changes in both cortical
and trabecular structure. In particular, cortical thickness and
porosity were strongly positively correlated with the change in
stiffness (r > 0.75, p<.01), whereas medullary area (Tb.Ar)
and Tb.N were strongly negatively correlated with the change
in stiffness (r< 0.70, p<.05). In the ALN group, the
Table 2. Spearman Correlations for 24-Month Percent Changes in Radius Measures for PBO and ALN
a
PBO (N¼13) ALN (N¼20)
Parameter %DD BSAP DuNTx %DK %DCt.LF DBSAP DuNTx %DK %DCt.LF
DXA
DTotal-spine aBMD 0.19 0.07 0.05 0.46  0.25 0.27  0.06 0.17
DTotal-femur aBMD 0.12 0.01 0.25 0.25  0.65
MM  0.09  0.14 0.28
DTotal-radius aBMD 0.75
MM 0.49  0.05 0.40 0.04 0.46
M 0.12 0.10
DUltradistal radius aBMD 0.45 0.14  0.05 0.62
M 0.07 0.54
M 0.15 0.20
HR-pQCT density
DvBMD 0.05  0.34  0.09 0.71
MM  0.26 0.19  0.05 0.36
DCt.vBMD  0.23  0.25 0.37 0.22  0.24  0.10 0.07  0.08
DTb.vBMD 0.32  0.14  0.41 0.76
MM 0.06 0.37  0.32 0.33
HR-pQCT geometry
DCt.Th
  0.03  0.36 0.01 0.64
M  0.27  0.07 0.20 0.29
DCt.Ar  0.04  0.43 0.04 0.62
M  0.36 0.20 0.15 0.32
DTb.Ar  0.07 0.37  0.10  0.54 0.29  0.16  0.16  0.37
HR-pQCT structure
DCt.PoV  0.12  0.28 0.75
MM  0.12  0.09  0.21 0.02 0.05
DCt.Po (%)  0.16  0.25 0.77
MM  0.17  0.08  0.21 0.05  0.01
DTb.N  0.12  0.21  0.59
M 0.89
MMMM  0.19 0.35  0.80
MMM 0.64
MM
DTb.Th 0.37 0.04 0.45  0.49 0.16  0.31 0.78
MMM  0.60
MM
DTb.Sp 0.02 0.19 0.59
M  0.92
MMM 0.19  0.32 0.79
MMM  0.60
MM
DTb.1/N.SD 0.01  0.04 0.47  0.65
M 0.02  0.33 0.56
M  0.51
M
HR-pQCT porosity biomechanics
DDKPO  0.20  0.27 0.42 0.23  0.26  0.19  0.21 0.18
DDEPO  0.23  0.32 0.38 0.25  0.29  0.16  0.23 0.21
DDFPO  0.62
M  0.26 0.35  0.21  0.14 0.12  0.03 0.10
DDCt.LFPO  0.43  0.23 0.85
MMM  0.46 0.04  0.36 0.13  0.44
aBold indicates statistically significant correlations with
 p<.05,
  p<.01,
   p<.001,
    p<.0001
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associated with trabecular and endocortical changes (Tb.Ar,
Tb.Th, Tb.1/N.SD; 0.50  j rj 0.61, p<.05).
Baseline predictors of the functional response to ALN
The Spearman rank correlation coefficient for each baseline
index with respect to the 24-month changes in biochemical
markers of bone turnover and mFEA-derived estimates of bone
strength are presented in Tables 4 and 5 for the distal radius and
tibia, respectively, for the ALN cohort.
In the distal radius (Table 4), baseline total radius aBMD,
Ct.TMD, and all cortical porosity measures were moderately well
correlated with baseline uNTx/Cr (p<.05). However, no baseline
HR-pQCT measures were found to correlate with the 24-month
change in the biochemical markers of bone turnover. In contrast,
moderate correlations were found between the 24-month
change in biomechanical indices and baseline cortical load
fraction (Ct.LF) and porosity-related parameters. In particular, the
change in the estimated failure load was positively correlated
with baseline Ct.LF, cortical pore volume (Ct.PoV), and all
estimates of porosity-related mechanical deficits (r   0.50,
p<.05).
In the distal tibia (Table 5), baseline Tb.vBMD and all porosity-
related volumetric and mechanical indices were positively
correlated with the 24-month change in BSAP (0.48  j rj 
0.56, p<.05). Biomechanical changes (%DE and %DCt.LF)
following 24 months of ALN treatment were significantly
correlated with baseline vBMD, Ct.vBMD, Ct.Ar, and Ct.Th
(p<.05) but not with any measure of trabecular or cortical
microarchitecture.
Discussion
This study reports longitudinal cortical and trabecular micro-
architecturalchangesrelatedtoantiresorptivetherapymeasured
by HR-pQCT. In general, ALN resulted in maintenance of vBMD in
the radius compared with PBO and a longitudinal increase in the
tibia, consistent with the observed reduction in resorption
measured by biochemical markers of bone turnover (uNTx). In
the radius, these findings also were consistent with the observed
maintenance in ultradistal aBMD measured by DXA.
The significant longitudinal increase in cortical thickness, area,
and load fraction in the distal tibia and corresponding decrease
in medullary area in the ALN-treated group are consistent with
the filling of endocortical bone resorption cavities. Both the
standard areal estimate of Ct.Th and the direct endosteal-
periosteal 3D measure were found to increase significantly with
respect to baseline in response to alendronate. On average,
cortical thickness increased by 30 mm (areal Ct.Th estimate) and
Table 3. Spearman Correlations for 24-Month Percent Change in Tibia Measures for PBO and ALN
a
PBO (n¼13) ALN (n¼20)
Parameter %DD BSAP DuNTx %DK %DCt.LF DBSAP DuNTx %DK %DCt.LF
DXA
DTotal-spine aBMD 0.19 0.07 0.38  0.03  0.25 0.27 0.18 0.26
DTotal-femur aBMD 0.12 0.01  0.06 0.36  0.65
MM  0.09 0.16 0.20
DTotal-radius aBMD 0.75
MM 0.49  0.44 0.51 0.04 0.46 0.26  0.42
DUltradistal radius aBMD 0.45 0.14 0.29  0.04 0.07 0.54
M  0.02  0.35
HR-pQCT density
DvBMD  0.05  0.25 0.59
M 0.11 0.02 0.27 0.19 0.37
DCt.vBMD 0.03  0.01 0.58
M  0.27 0.23 0.28 0.22 0.08
DTb.vBMD 0.04  0.23 0.05  0.10  0.14 0.10 0.10 0.56
MM
HR-pQCT geometry
DCt.Th
 
 0.17  0.43 0.76
MM 0.10  0.24  0.09 0.15 0.36
DCt.Ar  0.06  0.35 0.64
M 0.21 0.12 0.26 0.26 0.16
DTb.Ar 0.20 0.31  0.76
MM  0.05  0.03  0.12  0.50
M 0.01
HR-pQCT structure
DCt.PoV  0.03  0.25 0.68
M 0.16  0.18  0.41  0.15  0.06
DCt.Po  0.20  0.19 0.78
MM  0.11  0.08  0.39  0.14  0.14
DTb.N 0.51 0.53  0.71
M 0.63
M 0.00 0.04  0.37 0.63
MM
DTb.Th  0.52  0.48 0.69
M  0.78
MM  0.08 0.01 0.61
MM  0.43
DTb.Sp  0.45  0.54 0.69
M  0.64
M 0.03  0.06 0.35  0.63
MM
DTb.1/N.SD  0.30  0.46 0.07  0.21  0.03 0.11 0.50
M  0.40
HR-pQCT porosity biomechanics
DDKPO 0.15  0.06 0.48 0.15  0.19  0.43  0.52
M 0.13
DDEPO 0.12  0.06 0.54 0.12  0.20  0.43  0.51
M 0.11
DDFPO 0.08  0.09 0.38 0.23  0.03  0.49
M  0.32  0.07
DDCt.LFPO  0.22 0.15 0.50  0.19 0.11  0.46
M  0.10  0.24
aBold indicates statistically significant correlations with
 p<.05,
  p<.01,
   p<.001,
    p<.0001.
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 )coincidentwithareciprocaldecreaseintheradius
of the medullary compartment (data not shown). This suggests
that the increase in cortical thickness cannot be attributed
entirely to a decrease in intracortical porosity nor to an increase
in cortical matrix mineralization—neither of which should affect
Ct.Th
 .
In fact, no significant longitudinal changes in Ct.Po were
observed. It must be noted, however, that the spatial resolution
of HR-pQCT may be insufficient to directly detect longitudinal
changes in porosity on this scale. Furthermore, given the small
number of subjects and relatively low precision of Ct.Po
parameters (RMSCV¼4% to 11%), the study was not sufficiently
powered to detect longitudinal changes in porosity. Since
previous ex vivo studies using high-resolution micro–computed
tomography (mCT) have found significant changes in iliac crest
cortical porosity in response to bisphosphonate treatment,
(41)
higher-powered HR-pQCT studies are needed to determine
whether longitudinal changes in porosity are detectable.
Our results consistently indicated a greater trabecular and
cortical bone response to alendronate in the weight-bearing
distal tibia compared with the distal radius. This also was
reflected in the mFEA estimates of bone strength, which were
unchanged at 24 months at the tibia but significantly decreased
atthe radius comparedwith baseline. Animportant caveat ofthe
mFEA method applied in this study is that it assumed fixed,
homogeneous material properties. An advantage of this
approach is that it allowed specific interrogation of the
microarchitectural component of the biomechanical response
to treatment independent of material effects. Accordingly, the
scope of the analysis here was uniquely constrained to
investigating geometric and microarchitectural effects related
to ALN response. However, mineral compositional changes
associated with antiresorptive therapies are thought to be a
significant factor in their antifracture efficacy. Therefore, the
mFEA approach applied in this study likely underestimates the
true mechanical effects of alendronate.
A critical consideration in interpreting the longitudinal results
of this study is the limited statistical power owing to an
unexpectedly highattrition rate( 50%forPBO).Retrospectively,
power analysis indicated that 21 subjects per treatment group
were required to detect a 5% difference in the change in
Tb.vBMD, whereas only 13 PBO and 20 ALN subjects completed
the second year. Because trabecular and cortical measures of
bone microarchitecture are less precise than density, the lack of
longitudinal and treatment-wise effects for these measures
cannot be interpreted simply as a negative response. However,
our longitudinal data for density, geometry, and microarchi-
tectural changes in response to alendronate are remarkably
consistent with the results of a recent 12-month multicenter HR-
pQCTstudyinpostmenopausalwomentreatedwithalendronate
or denosumab.
(22) Furthermore, it is possible, despite no
significant difference between the final ALN and PBO groups
in baseline age, body mass index (BMI), BMD, and biochemical
markers of bone turnover, that the per-protocol analysis
introduced some selective bias.
A novel component of this study was the use of regional
analysis to provide anatomic localization of densitometric and
structural changes. Because of substantial axial variability in
density and bone morphology in these sites,
(33,42) it is likely that
certain regions provide greater sensitivity to treatment-related
alterations or biomechanical stimuli. Indeed, while global
measures of trabecular microarchitectural change did not reach
statistical significance between treatments, specific cortical and
trabecularregions(namely,thelateralandposteriorquadrantsof
the radius and tibia, respectively) were found to show significant
treatment effects in trabecular density and microarchitecture.
The locations of these effects were consistent with regions of
relatively low BV/TV and Tb.Th and are where the greatest age-
related differences have been observed in a recent cross-
sectional study.
(33)
While the MANOVA analyses provide discriminatory informa-
tion about treatment-induced alterations for independent
measures of bone quality, they do not provide direct insight
into how such alterations relate to functional efficacy. In general,
the correlation analysis revealed that the biomechanical
response to ALN treatment was primarily due to trabecular
Fig. 6. Scatter plot for the percent change in trabecular number against
the change in axial stiffness computed by mFEA following 24 months of
treatment with placebo (top) or alendronate (bottom). Both cohorts
exhibited moderate to strong Spearman correlation coefficients.
ap<.05;
bp<.01;
cp<.001;
dp<0.0001; otherwise, not significant.
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measureswerehighlycorrelatedwithbiomechanicalresponseto
ALN. In the tibia, in addition to trabecular structure, trabecular
cross-sectional area (Tb.Ar) and porosity-related biomechanical
deficits were negatively related to the overall biomechanical
response to ALN. Changes in DXA aBMD were only moderately
related to bone turnover changes and were relatively poorly
associated with biomechanical response to ALN at both sites.
These findings indicate that the response to ALN is primarily
reflected by trabecular bone structure effects.
Interestingly, despite a trend toward a modest mean increase
in trabecular number following 24 months of ALN treatment, the
correlation between the percent change in Tb.N and the change
in axial stiffness was found to be strongly negative for these
subjects (Fig. 6). It is important to recognize that, on average,
stiffness decreased significantly in the distal radius for the ALN-
treated group. A possible explanation for this is that the
anticatabolic action of ALN particularly inhibits resorptive
fenestration of trabecular plates. In nonresponsive (or non-
adherent) subjects with progressive early bone loss (osteopenia),
trabecular fenestration may effectively increase the number of
trabeculae through the conversion of a trabecular plate to
multiple trabecular rods. This suggests that ALN responders in
this early postmenopausal cohort maintained axial stiffness by
preventing fenestration of trabecular plates. While this explana-
tion may be consistent with early transient postmenopausal
changes in bone structure (plate-to-rod conversion), it would not
be expected to hold for elder osteoporotic cohorts, where bone
lossismoretypicallycharacterizedbylossofftrabecularrodsand
increased spacing.
(11) These observations highlight the complex
nature of structure-function relationships and underscore the
importance of investigating these interactions in a subject-
specific manner.
Thedevelopmentofnewtherapeuticagentsandthedesignof
single or combination treatment strategies require an under-
standing the biologic factors that determine the treatment
response. In general, baseline DXA aBMD measures were very
poorly correlated with response in both the radius and the tibia.
Table 4. Spearman Correlations for Baseline Radius Measures Against 24-Month Response to ALN
a
Biomarkers Biomechanics
Baseline parameter BSAP baseline uNTx baseline DBSAP DuNTx %DK %DE %DF %DCt.LF
Biomarkers
BSAP — 0.31
M  0.66
MMM  0.31  0.2  0.26  0.34 0.07
uNTx 0.31
M — 0.15  0.77
MMM 0.25 0.12 0.24  0.47
M
DXA
Total-spine aBMD  0.03 0.09 0.34 0.19 0.01 0.03 0.05  0.05
Total-femur aBMD  0.07 0.03 0.20 0.22  0.25  0.29  0.17 0.19
Total-radius aBMD  0.20  0.31
M  0.12 0.30  0.09  0.13  0.16 0.54
M
Ultradistal radius aBMD 0.04  0.10  0.15 0.13  0.13  0.22  0.24 0.49
M
HR-pQCT density
vBMD 0.03 0.20  0.10  0.27 0.14  0.06 0.00 0.01
Ct.vBMD 0.13  0.19  0.17  0.11 0.08  0.02  0.05  0.06
Tb.vBMD  0.14 0.15 0.22 0.04  0.22  0.37  0.32 0.31
HR-pQCT geometry
Ct.Th
  0.19 0.05  0.10  0.24 0.32 0.22 0.26  0.12
Ct.Ar 0.17  0.02  0.12  0.09 0.16 0.09 0.09 0.17
Tb.Ar  0.08  0.19  0.18 0.18  0.18  0.13  0.18 0.35
HR-pQCT structure
Ct.PoV  0.07 0.37
MM 0.25  0.01 0.35 0.42 0.48
M 0.04
Ct.Po (%)  0.12 0.34
M 0.29  0.05 0.31 0.37 0.43 0.02
Tb.N  0.18 0.10 0.32 0.02  0.06  0.19  0.12 0.33
Tb.Th  0.04 0.16 0.02  0.05  0.28  0.32  0.31 0.03
Tb.Sp 0.19  0.11  0.29  0.04 0.10 0.23 0.18  0.37
Tb.1/N.SD 0.18 0.00  0.27  0.25 0.36 0.44 0.43  0.47
M
HR-pQCT biomechanics
Stiffness K 0.06 0.15  0.18  0.12  0.25  0.32  0.30 0.50
M
Modulus E 0.01 0.15  0.25  0.38  0.01  0.17  0.13  0.04
Failure load F 0.05 0.12  0.19  0.16  0.30  0.40  0.38 0.46
M
Ct.LF 0.19 0.05  0.02  0.34 0.62
MM 0.62
MM 0.64
MM  0.74
MMM
DKPO  0.08 0.35
M 0.30  0.04 0.43 0.50
M 0.54
M  0.03
DEPO  0.09 0.34
M 0.35 0.02 0.47
M 0.55
M 0.58
M  0.06
DFPO  0.11 0.32
M 0.26  0.06 0.36 0.41 0.50
M 0.03
DCt.LFPO  0.17 0.28
a 0.26 0.18 0.08 0.14 0.23 0.35
aBold indicates statistically significant correlations with
 p<.05,
  p<.01,
   p<.001,
    p<.0001.
2568 Journal of Bone and Mineral Research BURGHARDT ET AL.In contrast, baseline cortical geometry and density showed
moderate to strong correlations with the biomechanical
response in the tibia, whereas baseline cortical load fraction
and porosity-related measures were significantly correlated with
biomechanical response in the radius. Only Tb.vBMD and cortical
porosity-related measures in the tibia correlated with the
response in terms of bone turnover changes (BSAP only). This
is consistent with a greater remodeling surface area available for
bone formation following retardation of osteoclastic activity.
Collectively, these results highlight the significance of cortical
bone status in predicting response to ALN. Specifically, in this
limited cohort, subjects with greater axial loads borne by the
cortex,greaterlevelsofintracortical porosity,andthicker cortices
were found to be associated with a greater response to ALN.
There areseveral technical limitations to this study that should
be acknowledged. First, common VOIs between baseline and
follow-up scans are determined based on 2D periosteal cross-
sectional area matching. This approach inherently assumes a
constant cross-sectional area between measurements. A change
in cross-sectional area via periosteal apposition would be
expected to introduce an erroneous longitudinal offset between
baseline and follow-up VOIs registered in this fashion. Recently,
Boydreportedapronouncedstructuralvariationalongthedistal-
proximal axis of the radius in the distal region measured by HR-
pQCT.
(43) Collectively, this raises the possibility of specific biases
inlongitudinalchangesdeterminedwitharea-basedregistration.
Full 3D image registration techniques, which have been shown
previously to moderately improve short-term reproducibility of
HR-pQCT measurements,
(44) potentially would improve true
region matching between longitudinal measurements. For this
study, it is worth noting that clinical doses of alendronate in
animal models have not been found to significantly increase
periosteal apposition and therefore cross-sectional area.
(45)
Accordingly, malregistration owing to periosteal changes is
not likely to be an important source of error.
A critical assumption of the standard analysis is a reliance on
fixed-intensity thresholds and the derivation of trabecular BV/TV
directly from Tb.vBMD. Alendronate has been found previously
Table 5. Spearman Correlations for Baseline Tibia Measures Against 24-Month Response to ALN
a
Biomarkers Biomechanics
Baseline parameter BSAP baseline uNTx baseline DBSAP DuNTx %DK %DE %DF %DCt.LF
Biomarkers
BSAP — 0.29
M  0.72
MMM  0.31 0.12 0.00 0.05 0.49
M
uNTx 0.29
M —  0.02  0.76
MMM 0.06 0.05  0.08  0.15
DXA
Total-spine aBMD  0.02 0.10 0.34 0.19 0.19 0.20 0.08 0.06
Total-femur aBMD  0.02 0.07 0.20 0.22 0.18 0.30 0.06  0.11
Total-radius aBMD  0.23  0.32
M  0.12 0.30 0.29 0.21 0.27 0.10
Ultradistal radius aBMD 0.01  0.13  0.15 0.13 0.10 0.09 0.07  0.01
HR-pQCT density
vBMD 0.02 0.11 0.12  0.07 0.29 0.52
M 0.20  0.62
MM
Ct.vBMD 0.17  0.24  0.36  0.12 0.35 0.50
M 0.28  0.27
Tb.vBMD  0.41
M 0.01 0.51
M 0.24 0.15 0.16 0.12  0.42
HR-pQCT geometry
Ct.Th
  0.22 0.13 0.05  0.29 0.19 0.46
M 0.10  0.57
MM
Ct.Ar 0.09 0.08 0.12  0.33 0.21 0.46
M 0.15  0.63
MM
Tb.Ar  0.28
M  0.22  0.10 0.19  0.18  0.42  0.06 0.49
M
HR-pQCT structure
Ct.PoV  0.11 0.26 0.56
M 0.05  0.14  0.15  0.06  0.17
Ct.Po (%)  0.11 0.27 0.46
M 0.14  0.16  0.24  0.06 0.05
Tb.N  0.15  0.08 0.20 0.39 0.18 0.02 0.11 0.17
Tb.Th  0.26 0.10 0.37  0.24  0.27  0.10  0.22  0.39
Tb.Sp 0.17 0.05  0.22  0.37  0.19  0.03  0.12  0.11
Tb.1/N.SD 0.10 0.13  0.06  0.41  0.24  0.08  0.07  0.05
HR-pQCT biomechanics
Stiffness K  0.20 0.13 0.07  0.36 0.03 0.21 0.00  0.55
M
Modulus E 0.06 0.23 0.12  0.33 0.03 0.33  0.06  0.65
MM
Failure load F  0.26 0.00 0.25  0.19  0.06 0.08  0.08  0.43
Ct.LF 0.41
MM 0.02  0.17  0.40 0.17 0.34 0.04  0.45
M
DKPO 0.01 0.31
M 0.51
B 0.09  0.06  0.09 0.02  0.04
DEPO 0.01 0.30
a 0.51
a 0.09  0.06  0.09 0.02  0.04
DFPO  0.04 0.28
a 0.53
a 0.09  0.05  0.11 0.01  0.05
DCt.LFPO  0.26 0.19 0.48
a 0.23  0.24  0.35  0.16 0.12
aBold indicates statistically significant correlations with
 p<.05,
  p<.01,
   p<.001,
    p<.0001.
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(46)This
has been shown to introduce moderate overestimation of
changes in Ct.Th when calculated based on the cortical area and
perimeter
(47) and also would be expected to result in an
overestimation of changes in densitometric trabecular BV/TV. As
discussed previously, direct 3D quantification of cortical
thickness was applied in this study in addition to the standard
areal estimate and confirmed a true affect on tibial cortical
geometry independent of matrix mineralization changes.
Recent phantom studies have found that Tb.vBMD measured
by HR-pQCT is subject to geometric biases (ie, cortical thickness)
likely related to beam-hardening and X-ray scatter.
(48) While this
is an important consideration for cross-sectional comparisons
with large biologic variability, it is not expected to be a
substantialsourceoferrorformeasuresoflongitudinalchangein
an individual. Whereas the range of Ct.Th (0.5 to 3.5 mm) and
Tb.vBMD (60 to 360 mg HA/cm
3) considered by Sekhon and
colleagues spanned broad cross-sectional extremes,
(48) the
longitudinal changes in Ct.Th and Tb.vBMD in this study were
very small by comparison (<4%).
In this study we have characterized the microarchitectural,
biomechanical, and bone turnover responses in early post-
menopausal, women with low bone density to an established
antiresorptive agent using noninvasive, high-resolution imaging.
Significant treatment effects were detected for global density,
but not microarchitectural properties. Changes in trabecular
microarchitecture, not changes in cortical bone, were more
highly correlated with ALN-related biomechanical response.
However, the biomechanical response to ALN was significantly
positively related to baseline cortical bone porosity in the radius
and cortical geometry and density in the tibia rather than to
baseline trabecular bone phenotypes. The dichotomous nature
of the prediction of the therapeutic response and the actual
manifestation of that response are important observations that
could recommend and inform future clinical research directions
significantly, including treatment customization and combina-
tion strategies that take into account cortical and trabecular
structure phenotypes. In a hypothesis-generating study, these
observations highlight the potential wealth of information high-
resolution imaging techniques bring to clinical research.
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